Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Autus Valve Frühe Machbarkeitsstudie

15. Oktober 2026 aktualisiert von: Edwards Lifesciences

Autus größenverstellbare Klappe für den chirurgischen Pulmonalklappenersatz Frühe Machbarkeitsstudie

Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.

The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.

Studienübersicht

Status

Aktiv, nicht rekrutierend

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

62

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • California
      • Los Angeles, California, Vereinigte Staaten, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • Children's Hospital Colorado
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30322
        • Children's Healthcare of Atlanta
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60611
        • Ann and Robert H. Lurie Children's Hospital of Chicago
    • Massachusetts
      • Boston, Massachusetts, Vereinigte Staaten, 02115
        • Boston Children's Hospital
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48109
        • University of Michigan - Mott Children's Hospital
    • New York
      • New York, New York, Vereinigte Staaten, 10032
        • Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital
    • North Carolina
      • Durham, North Carolina, Vereinigte Staaten, 27703
        • Duke University
    • Ohio
      • Columbus, Ohio, Vereinigte Staaten, 43205
        • Nationwide Children's Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19104
        • Children's Hospital of Philadelphia
    • Utah
      • Salt Lake City, Utah, Vereinigte Staaten, 84113
        • University of Utah - Intermountain Primary Children's Hospital
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98105
        • Seattle Children's Hospital

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

1 Jahr bis 16 Jahre (Kind)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.

  1. Age 18 months to 16 years.

  2. Male or female.

  3. Subject has a native or repaired right ventricular outflow tract.

  4. Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).

  5. Subject has at least one of the following echocardiographic findings:

    1. Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
    2. Moderate or greater pulmonary regurgitation;
    3. Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
  6. Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).

  7. Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.

  8. Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.

Exclusion Criteria:

Candidates will be excluded from the study if any of the following conditions are met:

  1. Subject requires valve replacement in a non-pulmonary position.
  2. Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
  3. Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
  4. Subject has pulmonary atresia and major aortopulmonary collaterals.
  5. Subject has significant peripheral pulmonary artery stenosis.
  6. Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
  7. Subject has active endocarditis or a history of infective endocarditis.
  8. Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
  9. Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
  10. Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L).
  11. Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.
  12. Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.
  13. Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
  14. Subject needs emergency cardiac or vascular surgery or intervention.
  15. Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
  16. Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
  17. Subject or parent/legal representative refuses blood transfusions.
  18. Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
  19. Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Autus Valve Arm

Pulmonary Valve Replacement Surgery with the Autus Valve

Pulmonary valve replacement surgery with the Autus Valve

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Valve Implantation Primary Safety Endpoint
Zeitfenster: 30 Days post-valve implantation

Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
30 Days post-valve implantation
Valve Implantation Primary Effectiveness Endpoint
Zeitfenster: 6 Months post-valve implantation

Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:

  • A mean RVOT gradient less than or equal to 40 mmHg and
  • Less than moderate pulmonary regurgitation by transthoracic echo and
  • No Autus Valve reintervention except for valve expansion to address prosthesis-patient mismatch.
6 Months post-valve implantation

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Other Safety Outcome - Composite
Zeitfenster: 6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:

  • Death;
  • Valve thrombosis requiring intervention;
  • Symptomatic thromboembolism.
6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Mortality
Zeitfenster: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Mortality, including: all cause, cardiac-related, procedure-related and device-related

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve Thrombosis
Zeitfenster: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Valve thrombosis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Thromboembolism
Zeitfenster: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Thromboembolism

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Cardiac or Valve Intervention
Zeitfenster: 30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Other cardiac or valve intervention (surgical or transcatheter)

30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
Other Safety Outcome - Major Hemorrhage
Zeitfenster: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Major hemorrhage

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Endocarditis
Zeitfenster: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Endocarditis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Hemolysis
Zeitfenster: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Hemolysis

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Device Explantation
Zeitfenster: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Device explantation

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Adverse Events (AE)
Zeitfenster: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation

The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year.

• Adverse events

30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
Other Safety Outcome - Valve/Stent Fracture
Zeitfenster: pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.

An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure.

pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
Other Effectiveness Outcome - Valve Implant Acute Procedural Success
Zeitfenster: Immediately Post-Valve Implant Procedure

To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):

  • RV to PA peak systolic pressure gradient <40 mmHg (direct pressure measurement);
  • None or trivial pulmonary regurgitation (assessed via TEE);
  • No paravalvular leak (assessed via TEE).
Immediately Post-Valve Implant Procedure
Other Effectiveness Outcome - Pulmonary Regurgitation Grade
Zeitfenster: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Pulmonary Stenosis Grade
Zeitfenster: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Right Ventricular Measures
Zeitfenster: Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Left Ventricular Measures
Zeitfenster: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory.

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - Modified Ross Functional Classification
Zeitfenster: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.

Modified Ross Functional Class as assessed by the Site Investigators

Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
Other Effectiveness Outcome - PedsQL - Cardiac Module
Zeitfenster: Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.

The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel.

Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
Other Post-Implant Valve Expansion Safety Outcome - Composite
Zeitfenster: 30 days after each post-implant valve expansion procedure

Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:

  • Death;
  • Extracorporeal membrane oxygenation (ECMO) support;
  • Unplanned intervention (surgical or transcatheter);
  • Major hemorrhage
30 days after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success
Zeitfenster: Immediately after each post-implant valve expansion procedure

To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:

  • RV to aortic systolic pressure ratio: ≤0.5.
  • Peak-to-peak RV to PA systolic pressure gradient: ≤15 mmHg;
  • Peak-to-peak RV to PA systolic pressure gradient: ≥50% reduction (pre vs post valve expansion).
Immediately after each post-implant valve expansion procedure
Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance
Zeitfenster: 6 months after each post-implant valve expansion procedure

Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:

  • Less than moderate pulmonary regurgitation (PR) by Doppler echocardiography;
  • Transvalvular gradient (assessed by CW Doppler) at 6-months is lower than the pre-expansion gradient.
6 months after each post-implant valve expansion procedure

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

5. Februar 2024

Primärer Abschluss (Tatsächlich)

24. August 2026

Studienabschluss (Geschätzt)

5. Februar 2036

Studienanmeldedaten

Zuerst eingereicht

23. Juli 2021

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

12. August 2021

Zuerst gepostet (Tatsächlich)

16. August 2021

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

20. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. Oktober 2026

Zuletzt verifiziert

1. Oktober 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • AUT-CP-001

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Ja

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .